Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Ethicon, Gmbh

Jens Schröder

Wilhelm Bone

Hans Briem

Anne Mengel

Gerhard Siemeister

Simon Holton

Marion Hitchcock

Ursula Mönning

Amaury Ernesto Fernandez-Montalvan

Lars Bärfacker

Volker Schulze

Cornelia Preuβe

Philip Lienau

Ulf Bömer

Knut Eis

Clara Christ

Ulrich Klar

Thomas Ernst Müller

Hans-Georg Lerchen

Dirk Kosemund

Markus Berger

Joachim Kuhnke

Matthew Meyerson

Benjamin Bader

Antje Margret Wengner

Arwed Cleve

Marcus Koppitz

Detlev Sülzle

Helmut Sonnenschein

Susanne Landgrebe

Barbara Schuldt-Hempe

Roman Hillig

Detlef Stöckigt

Keith Graham

Stefan Kaulfuss

Heinz Graubaum

Heidi Greulich

Stephan Siegel

Tobias Heinrich

Julien Lefranc

Burkhard Peters

Ulrike Rauh

Horst Irlbacher

Michael Niehues

Anja Richter

Manfred Möwes

Daniel Korr

Steven Corsello

Cornelia Preusse

Christian Lechner

Steven M Corsello

Bethany Kaplan

Jozsef Bálint

René Tempel

Amaury Ernesto Fernández-Montalván

Florian Prinz

Joszef Bálint

Adelaide Clara Faria Alvares De Lemos

Katarzyna Handing

Alisha Caliman

Franziska Siegel

Jérémie Xavier G Mortier

Jérémie Mortier

Hassan Y Harb

Ashley Eheim

Lars BÄRFACKER

Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1α and/or β) useful for the treatment of proliferative disorders.

3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients. 

Heteroarylbenzimidazole compounds

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones

Compounds of formula (I) as defined herein and their use as pharmaceuticals. 

Benzyl substituted indazoles as BUB1 inhibitors

Compounds of formula (I), and their use as pharmaceuticals. 

Substituted benzylpyrazoles

Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. 

Heteroaryl substituted pyrazoles

Compounds of formula (I), processes for their preparation and their use as pharmaceuticals. 

Growing community of inventors

Berlin, Germany

Jens Schröder